Investor Presentaiton slide image

Investor Presentaiton

Clinical Development Portfolio - Phase III OPDIVO OPDIVO+YERVOY OPDUALAG ✦ SC nivolumab + relatlimab + rHuPH20 ✦ SC nivolumab + rHuPH20 (multi-indications) + ABECMA iberdomide mezigdomide REBLOZYL CAMZYOS + milvexian ✦ cendakimab LPA1 Antagonist ✦ obexelimab * # SOTYKTU ZEPOSIA ll, Bristol Myers Squibb Q3 2023 Results Phase III Adjuvant Hepatocellular Carcinoma Peri-adjuvant Muscle-Invasive Urothelial Carcinoma Peri-adjuvant Non-Small Cell Lung Cancer Stage IB-IIIA Adjuvant NSCLC* 1L Hepatocellular Carcinoma 1L Muscle Invasive Urothelial Carcinoma 1L+ Microsatellite Instability High Colorectal Cancer Stage 3 Unresectable Non-Small Cell Lung Cancer Adjuvant Melanoma 2L/3L+ Metastatic Colorectal Cancer 1L Melanoma 2L Renal Cell Carcinoma Newly Diagnosed Multiple Myeloma with Suboptimal Response post-ASCT +2L+ Multiple Myeloma Post-Autologous Stem Cell Therapy Maintenance Newly Diagnosed Multiple Myeloma +2L+ Multiple Myeloma Vd 2L+ Multiple Myeloma Kd 1L TD Myelofibrosis Associated Anemia 1L NTD Myelodysplastic Syndrome Associated Anemia Non-Obstructive Hypertrophic Cardiomyopathy Secondary Stroke Prevention* Acute Coronary Syndrome* Atrial Fibrillation* Eosinophilic Esophagitis Eosinophilic Gastroenteritis # Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis (PPF) IgG4-Related Disease Psoriatic Arthritis Systemic Lupus Erythematosus Sjögren's Syndrome Crohn's Disease repotrectinib ABECMA REBLOZYL * Oncology Data as of October 26th, 2023 Registration US, EU, JP ROS1 NSCLC (US, JP) 3-5L Multiple Myeloma (US, EU, JP) 1L TD Myelodysplastic Syndrome Associated Anemia (EU, JP) Hematology CV Neuroscience Immunology Partner-run study ✦ NME leading indication # Certain Asian territories Development Partnerships: ABECMA: 2seventy bio; AHR: Ikena Oncology; Anti-MTBR-Tau: Prothena; CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; farletuzumab ecteribulin: Eisai; rHuPH20: Halozyme; MAGEA4/8 TCER: Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO, YERVOY, OPDUALAG in Japan: Ono; PKCO Inhibitor: Exscientia; REBLOZYL: Merck; SHP2 Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; obexelimab: Zenas BioPharma in Japan, South Korea, Taiwan, HK, Singapore, and Australia Not for Product Promotional Use 30
View entire presentation